Treatment of Vulvar Intraepithelial Neoplasia in Immunosuppression

Immunosuppressed patients with vulvar intraepithelial neoplasia (VIN) represent a distinct clinical subgroup requiring prompt and active management. The coexistence of immunocompromised states alters the natural course and risk profile of VIN in meaningful ways.

Clinical Scenario

      In immunosuppressed patients, VIN lesions tend to be more severe, are less likely to regress spontaneously, carry an increased risk of progression to invasive cancer, and are associated with a higher recurrence rate.
    

Treatment is therefore actively indicated in this setting — watchful waiting strategies appropriate in immunocompetent individuals are not similarly applicable here.

Treatment Approach

Lesion excision is the treatment of choice. Depending on the extent and location of lesions, ablative approaches or combinations thereof may be considered in selected cases — particularly when surgical excision alone would compromise critical anatomical areas.

Full treatment algorithm, selection criteria, and complete clinical guidance available in the structured protocol…

Instant Access to Structured Evidence-Based Regimens

References

The treatment of VIN in immunosuppressed patients is justified by the increased severity of the lesions, less likelihood of regression, an increased risk of progression to invasive cancer and a higher recurrence rate.

The treatment of choice is lesion excision.

In selected cases with widespread lesions or with specific compromised areas, ablative or combined treatments with CO2 laser vaporization may be used.

These treatments are used in cases in which ablative or surgical treatment compromises vulvar anatomy or functionality as in cases in which the lesions include anatomical areas such as the urethra, clitoris and non-hairy areas.

View source ↗